Antiretroviral Drugs and Risk for MI in HIV-Infected Patients
In addition to confirming duration of combination therapy as a risk factor, the DAD Study Group implicated protease inhibitors specifically.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)